An update on immunotherapy in uro-oncology

Expert Review of Precision Medicine and Drug Development · Published 2021-05-03 · DOI 10.1080/23808993.2021.1911638

Authors being retrieved — see the publisher record. https://doi.org/10.1080/23808993.2021.1911638

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2021

Related articles

• PD-L1 assessment in breast cancer immunotherapy: a critical overview · Expert Review of Precision Medicine and Drug Development · 2022 · Same journal
• Precision Medicine Paradigms in Allergic Rhinitis: Navigating Immunotherapy and Digital Healthcare · Expert Review of Precision Medicine and Drug Development · 2024 · Same journal
• Mutation-dependent treatment approaches for patients with complex multiple myeloma · Expert Review of Precision Medicine and Drug Development · 2021 · Same journal
• Advanced laboratory techniques in diffuse large B-cell lymphoma treated with CAR-T: the role for pathologists · Expert Review of Precision Medicine and Drug Development · 2024 · Same journal
• GUCY2C as a biomarker to target precision therapies for patients with colorectal cancer · Expert Review of Precision Medicine and Drug Development · 2021 · Same journal
• Personalizing treatments for patients based on cardiovascular phenotyping · Expert Review of Precision Medicine and Drug Development · 2022 · Same journal
• Tumor growth rate to assess therapy response to immune-based combinations for metastatic renal cell carcinoma · Expert Review of Precision Medicine and Drug Development · 2024 · Same journal
• Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer · Expert Review of Precision Medicine and Drug Development · 2022 · Same journal
• Dopaminergic and other genes related to reward induced overeating, Bulimia, Anorexia Nervosa, and Binge eating · Expert Review of Precision Medicine and Drug Development · 2021 · Same journal
• Abiraterone acetate plus prednisone/prednisolone in hormone-sensitive and castration-resistant metastatic prostate cancer · Expert Review of Precision Medicine and Drug Development · 2020 · Same journal